Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 24, 2010Antimicrobial Agents and ChemotherapyOpen Access

Impact of cyp51A Mutations on the Pharmacokinetic and Pharmacodynamic Properties of Voriconazole in a Murine Model of Disseminated Aspergillosis

View Full Paper
Ask AI
Bookmark
Share

Authors

EMEleftheria MavridouPanagiotis & Aglaia Kyriakou Children's HospitalRBRoger J. M. BrüggemannRadboud University NijmegenWMWillem J. G. MelchersStatens Serum Institut

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Mavridou et al. (2010) studied this question.

synapsesocial.com/papers/6a6f86ab26770c2b8de00a06https://doi.org/10.1128/aac.00606-10
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy of Posaconazole against Three Clinical Aspergillus fumigatus Isolates with Mutations in the cyp51A Gene2009 · 112 citations
  2. 2Frequency and Evolution of Azole Resistance in Aspergillus fumigatus Associated with Treatment Failure12009 · 758 citations
  3. 3Voriconazole, a novel wide‐spectrum triazole: oral pharmacokinetics and safety2003 · 148 citations
  4. 4Multiple-Triazole–Resistant Aspergillosis2007 · 381 citations
  5. 5State‐of‐the‐Art Clinical Article: Pharmacokinetic/Pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and Men1998 · 2,921 citations